Surgical treatments are an important consideration in the management of many movement disorders, particularly for patients refractory to medications. Increasing number of published reports have demonstrated an overall improvement in motor function, activities of daily living and quality of life particularly with deep brain stimulation. In addition the procedure is also relatively safe. In this article, we review the various types of movement disorders that may benefit from surgical intervention.
InTrODucTIOn
Surgery has become a well-established form of therapy in movement disorders particularly for Parkinson's disease (PD) and essential tremor (ET) patients with symptoms that are refractory to medications or who have intolerable side effects related to medical therapy. Other movement disorders including dystonia, tremors associated with multiple sclerosis and tics seen in Tourette's syndrome (TS) also appear to benefit from stereotactic surgery. This review article will provide an overview of various movement disorders with an emphasis on those that may benefit from neurosurgical interventions.
Parkinson's Disease
Clinical Features PD has classical motor features which include rest tremor, rigidity, bradykinesia and postural instability 1 . The disease onset is slow and the deficits usually remain asymmetric. It has a gradual progression and a sustained response to dopaminergic medications. Pathologically, neuronal loss predominates in the substantia nigra zona compact; this leads to decreased dopamine in the striatum with a rostrocaudal gradient (maximum loss caudally).
Apart from motor dysfunction, patients with PD also have a wide spectrum of non-motor manifestations due to varied patterns of degeneration in dopaminergic (mesolimbic, mesocortical) and nondopaminergic (cholinergic, noradrenergic, serotoninergic) neuronal systems 1 . These nonmotor manifestations may occur early in the disease but are generally more disabling later on with disease progression and include fatigue, cognitive decline, depression, anxiety, behavioural disturbances, visual dysfunction, dysautonomia, weight loss, sleep abnormalities, abnormal sensations and pain 2 .
Medical Therapy PD has good response to medical therapies in the early stages. They include anticholinergic drugs, dopamine agonists, levodopa, monoamine oxidase-B, catechol-O-methyl transferase inhibitors and others. With progressive degeneration, PD patients develop motor and non-motor features which are less responsive to medications. They also develop complications related to the long-term medications that include motor fluctuations and dyskinesias. Motor fluctuations consist of variation in clinical status that occurs hour to hour over the course of a day and dyskinesia refers to abnormal Review Proceedings of Singapore Healthcare  Volume 19  Number 4  2010 involuntary movements (typically mixtures of chorea, athetosis and dystonia) occurring in association with medication therapy. Such patients may rapidly alternate between "off-periods" and "on-periods" with dyskinesias. The periods of optimal balance become shorter or absent as the disease progresses. It is these patients that benefit significantly from surgical procedures.
Surgical Therapy
Stereotactic surgical procedures were introduced in the 1940s 3 . Different targets in the brain were explored to control PD symptoms. However there was a rapid decline in these procedures after levodopa was introduced in 1967. There was marked improvement of motor symptoms and reduction of morbidity and mortality with levodopa. However, with the long-term use of levodopa patients often developed disabling motor fluctuations and dyskinesia. With the better understanding of basal ganglia circuitry, improved neuroimaging and electrophysiological recording techniques surgical therapy in PD has resurged. As a rule, PD patients who respond to levodopa but have motor fluctuations and/or dyskinesia that cannot be controlled with medications as well as patients with disabling and medically resistant tremor are candidates for surgery 4 . However, symptoms unresponsive to levodopa (e.g., postural reflex impairment, hypophonia/ dysarthria, swallowing, and mentation) will most likely not improve with surgery. Major exclusion for surgery, include significant cognitive, behavioral and psychiatric problems such as active severe depression as well as important concomitant medical illnesses ( Table 1) .
The surgeries available for PD patients are ablative surgery and deep brain stimulation (DBS) 5, 6 . The ablative surgeries include thalamotomy, pallidotomy and subthalamotomy. They are relatively cheaper compared to DBS and so are favoured in less developed countries. However, nowadays DBS has out-fashioned the ablative surgeries due to its advantages, particularly in adjustability and reversibility ( Table 2) . Deep brain stimulation is a surgical procedure involving implantation of electrodes into deep nuclei of the brain (Fig. 1 ). The electrodes are placed under local anaesthetics, using stereotactic or computer-assisted guidance techniques. Either framed or frameless system, are used for stereotactic targeting. Intraoperative microelectrode recording of single neurons is often performed to verify the correct physiological target location, and test stimulation is used to confirm therapeutic benefit and to evaluate side effects. Several electrode passes may be required to refine the target location.
Once correct physiological targeting has been confirmed, the electrodes are permanently anchored in place. Electrodes may be placed unilaterally or bilaterally, depending on the disease being treated and the individual patient's symptomatology. The electrodes are then connected to a computerized pulse generator that is implanted subcutaneously, in a manner similar to that used for a pacemaker. Pulse generator implantation is performed either contemporaneously with electrode placement or as a staged procedure at a later date. Post-surgically a movement disorders specialist with knowledge and experience in DBS programming will adjust the stimulation parameters to maximise therapeutic effects with minimal side effects. 7 . Thalamic stimulation may be considered for patients with predominantly disabling tremors (that are medication resistant) and have minimal signs of bradykinesia and rigidity, as these latter symptoms do not improve with thalamic stimulation. However most tremor-predominant patients are eventually impaired by these other symptoms and so Vim surgery has been largely abandoned in PD except for elderly patients with long standing disabling tremor. GPi stimulation has been shown to improve tremor, bradykinesia and rigidity and markedly reduce levodopainduced dyskinesia. However, the benefit may not be sustained. Moreover, GPi DBS does not lead to reductions in the patient's levodopa requirement. In fact, a long-term study with average follow-up of 32 months found that medication requirement increases after chronic GPi DBS therapy 8 . Therefore, the most common surgical target for PD is now the STN. DBS of the STN improves all motor symptoms, which include tremor, bradykinesia, rigidity, posture and gait in the medication off state. There is also marked improvement of dyskinesia (largely due to reduction in anti-parkinsonian medications after surgery) 9 and duration of "on" time. The activities of daily living as well as quality of life also improved significantly. The best predictor of this response is the preoperative Recent reports have suggested an important role for the pedunculopontine nucleus (PPN), in the development of motor symptoms, such as akinesia, gait dysfunction and postural instability 11 . The PPN is part of the mesencephalic locomotor reticular region 12 and maintains dense interconnections with the basal ganglia and several other pontine and medullary areas 13, 14 . Preliminary open-label evaluations of PPN DBS in a very small number of patients have provided promising results 15 .
DBS targets in PD include the thalamus (ventral intermediate (Vim) nucleus), globus pallidus interna (GPi) and subthalamic nucleus (STN)
Other surgical therapies in PD are either in the experimental or early stages. These include motor cortex stimulation, intraparenchymal drug delivery, gene and cell based therapies. With regards to fetal transplants, the results have been disappointing. Although there was evidence of post-transplant survival and graft growth based on Fluorodopa (FDOPA) PET scan, but the primary endpoint of motoric improvement was negative 16 .
Tremor

Definition and Types of Tremors
Tremor is defined as an involuntary, rhythmic, and sinusoidal oscillation of one or more body parts produced by alternating or synchronous contractions of agonist and antagonist muscles. It is classified as resting or action tremor. A resting tremor is a tremor in a limb that is in a resting position, with its weight fully supported against gravity. It is typically seen in parkinsonism, more commonly in Parkinson's disease than other parkinsonian syndromes. Action tremor is further divided into postural, kinetic or intention tremor. A postural tremor is seen with the maintenance of a posture, against gravity while a kinetic tremor is seen with a voluntary movement of the limb. Intention tremor increases in amplitude when approaching a target.
Essential tremor (ET) is the commonest pathological form of action tremor in movement disorders. The prevalence ranges from 0.4% to 6.7% in persons over 40 years. It is usually symmetrical bilaterally with a frequency of 4 Hz to 12 Hz 17 . The upper limbs are affected in about 95% of patients, followed by head (34%), lower limbs (20%), voice (12%), face and trunk (5%) 18 . A diagnosis of dystonic tremor should be strongly suspected when tremor of the head occurs in isolation or precedes the development of hand tremor. With the passage of time, the frequency of the tremor in ET decreases and the amplitude may increase 19 .
A majority of ET patients note a profound reduction of tremor in response to alcohol but this is temporary and may be followed by rebound worsening.
In multiple sclerosis (MS), tremor can be seen in the upper extremities (55%), lower extremities (8%), head (7%) and trunk (5%) 20 .
The pathophysiology of tremor in MS is not fully understood 21 . It is often one component in a complex movement disorder that includes dysmetria and other ataxia features [22] [23] [24] [25] [26] . The tremor is generally believed to be cerebellar in nature and accompanied by other cerebellar, sensory and corticospinal impairment 27 .
Holmes' tremor, previously known as midbrain tremor, rubral tremor, thalamic tremor, myorhythmia, and Benedikt's syndrome 28 , predominantly occurs in proximal limbs. It is of low frequency (<4.5 Hz), commonly with a rest component that clearly worsens with postural maintenance, worsening still during movement and goal directed tasks. Holmes' tremor is almost always attributable to lesions in upper brain stem, thalamus, or cerebellum, interrupting pathways in the midbrain tegmentum (rubro-olivocerebellorubral loop, rubrospinal fibres, dopaminergic nigrostriatal fibres and the serotonergic brain stem telencephalic fibres). The disability of these patients is extreme, because they are neither able to keep their hands still nor can they reach and grasp, when the syndrome is fully expressed.
Medical Therapy
The two most often used drugs in ET are nonselective β-blockers (for example, propranolol) and primidone. They are significantly effective and generally well tolerated [29] [30] [31] [32] [33] [34] . Apart from these first line drugs, topiramate, gabapentin and alprazolam have also been used as monotherapy or adjunctive treatment 35 . Intramuscular injections of botulinum toxin have been considered in medically resistant cases especially for head and voice tremor 36 general, the less pronounced the symptoms, the better the chances of a favourable outcome with medical treatment for patients with ET. However in a minority of patients the disability becomes unacceptable despite medical therapy when the tremor significantly interferes with feeding, drinking, and writing, or, in the case of vocal tremor, disrupts communication.
The results of medical treatment for MS tremor are often less than satisfactory. Several drugs (including drugs used for ET as well as odansetron, isoniazid, physostigmine, carbamazepine, and clonazepam) have been tried but with variable success [37] [38] [39] . The progressive nature of the disease makes medical treatments generally unrewarding. Similarly, it is also difficult to treat a Holmes' tremor.
Surgical Therapy
In medically refractory tremulous patients, stereotactic neurosurgery typically involving the thalamus may provide benefit. An alternative to "open" surgery is gamma knife thalamotomy which may be useful in elderly patients with medical contraindications to more conventional thalamotomy or DBS. ET patients with pure postural tremor of the upper extremities are highly likely to improve after either lesioning [40] [41] [42] [43] [44] [45] [46] or DBS [47] [48] [49] [50] [51] [52] [53] [54] of the VIM or the subthalamic area 55 .
If intention tremor or a more proximal tremor predominates, the success rate of surgery is slightly decreased. If head, voice, or trunk tremors are the main indications for surgery, a bilateral procedure is usually necessary [56] [57] [58] and bilateral DBS is favoured over thalamotomy as the latter carries higher risk of complications although bilateral thalamic DBS does have a moderate risk of dysarthria 59, 60 .
In refractory cases of tremor in MS patients, thalamotomy and chronic DBS of the VIM (or less commonly nucleus ventralis oralis posterior and zona incerta or subthalamic area) may provide benefit 61 . However, complete cessation of tremor is generally not achieved. Similarly surgical treatment of Holmes' tremors with stereotactic radiofrequency lesioning (posteroventral pallidotomy) and high frequency thalamic stimulation has been reported [62] [63] . However, there is some uncertainty about favourable response and much depends on the extent of the causative lesion and the specific symptom pattern of the patients.
Dystonia
Definition and Classification
Dystonia is defined as a neurological syndrome characterised by involuntary, patterned, sustained, or repetitive muscle contractions of opposing muscles, causing twisting movements and abnormal postures. Dystonias are classified based on anatomical distribution (focal, segmental, or generalised), age at onset, aetiology, and genetics 64, 65 . Childhood-onset dystonia usually progresses from focal limb dystonia to a severe generalised form, whereas dystonia that begins after the age of 25 years usually involves craniocervical muscles, remains localised or segmental, and is usually non-progressive 65 .The classification based on etiology includes primary dystonia, secondary dystonia, dystonia-plus syndromes, and paroxysmal dystonia 65 . The genetic classification is based on the loci of genes involved (loci DYT1 through DYT28) that include autosomal dominant, autosomal recessive and X-linked causes of primary dystonia, dystonia-plus syndromes and paroxysmal dystonias.
Medical Therapy
Medical treatment for dystonia can be subdivided into oral drugs and local botulinum toxin injections. Oral medications are the first line therapy especially in patients with childhood and adolescent-onset dystonia. Patients with doparesponsive dystonia (DRD) dramatically respond to levodopa, and a levodopa trial should be performed in all early-onset dystonia patients. However, levodopa usually does not improve or may even worsen other forms of dystonia. The first treatment of choice for non-DRD dystonia is usually anticholinergics with about 40±50% of patients showing a moderate response (high doses are usually required) 66, 67 . Other drugs include benzodiazepines (diazepam, clonazepam), gamma aminobutyric acidergics (baclofen), atypical neuroleptics (clozapine, olanzapine) and even typical neuroleptics (e.g. haloperidol) in very disabled patients 68, 69 . Dopamine depletors such as tetrabenazine may be of particular benefit in tardive dystonia 70 . Most focal dystonias are relatively unresponsive to systemic drug treatment but are frequently well controlled by periodic botulinum toxin (BTX) injections into the muscles directly involved in the dystonia 70 . If oral medications and botulinum toxin fail, in appropriately chosen disabled patients, intrathecal baclofen may be considered. Intrathecal baclofen may be especially Review Proceedings of Singapore Healthcare  Volume 19  Number 4  2010 useful for patients with secondary forms of dystonia who have additional spasticity.
Surgical Therapy
Stereotactic radiofrequency ablations of the thalamus or the pallidum used to be the preferred surgical methods to treat patients with severe and otherwise medically refractory dystonia. However, presently, deep-brain stimulation of the GPi is the preferred surgical treatment for dystonia because it has a lower risk of complications and the stimulation parameters can be customised for each individual patient. The improvement of dystonia following DBS implants follows a specific sequence. The dystonic movements (including phasic, myoclonic and tremulous features) may improve immediately or within hours or days after surgery but dystonic postures (i.e. tonic features) generally have a delayed improvement over weeks to months [71] [72] [73] . When pain is present (most often with cervical dystonia) it usually responds very early. Primary generalised dystonia seems to respond better than secondary dystonia to GPi-DBS. Also patients with cervical dystonia 74 , pantothenate kinase associated neurodegeneration 75 , and tardive dystonia 76 have been reported to have significant improvement with DBS. Apart from the GPi, the ventrolateral thalamus for secondary dystonia and subthalamic nucleus for primary dystonia have also been considered for surgical targets 77, 78 .
In addition to stereotactic procedures targeting thalamus and globus pallidus, peripheral denervation procedures have been used extensively in the past especially for focal and segmental dystonias. However, nowdays, these dystonias are treated with periodic BTX injection.
Other Movement Disorders
Chorea Chorea refers to irregular, flowing, nonstereotyped, random, involuntary movements that often possess a writhing quality referred to as choreoathetosis. In clinical practice, Huntington's disease is an important cause of adult-onset chorea. It is an autosomal dominantly inherited neurodegenerative disorder characterised by the triad of movement disorders, dementia, and behavioural disturbances.
Current treatments in Huntington's disease are largely symptomatic, aimed at reducing the motor and psychological dysfunction of the individual patient. Various drugs may be used including olanzapine, risperidone, haloperidol, tetrabenazine, amantadine and possibly riluzole to improve chorea 79 . The selective serotonin reuptake inhibitors (SSRIs) are used in treatment of depression while the atypical antipsychotic agents, such as clozapine, quetiapine, and olanzapine are used to treat psychosis in Huntington's disease 80 . In severely affected HD patients who have failed various medical treatments, surgery may be a possible option. There have been recent reports of bilateral pallidal stimulation in severely affected and medically intractable HD patients that produced a significant reduction in choreoathetoid movements, dystonia and improvement in overall motor functioning 81, 82 .
Pallidal lesioning or DBS may also be considered for other disabling drug resistant choreic disorders especially when caused by a static or nonprogressive cause. For example, rare patients with persistent hemiballism may be candidates for unilateral GPi surgery (DBS or lesions) while patients with disabling tardive dyskinesia (usually with more prominent dystonic components) may improve considerably with bilateral GPi DBS.
Tics and Tourette's syndrome
Tics are sudden, brief, intermittent, involuntary or semivoluntary movements (motor tics) or sounds (phonic or vocal tics). Motor tics are stereotyped repetitive involuntary or semivoluntary movements that typically involve the face, head, and upper body. Phonic (vocal) tics are sounds such as sniffing, grunting, or barking that are associated with muscle contractions of the oropharynx and diaphragm. Tourette's syndrome (TS) is characterized by multiple motor and vocal tics that wax and wane over time.
Most tics do not require drug treatment. However, when the tics become a source of physical or emotional disability they require treatment. The standard treatment is pharmacologic involving mainly neuroleptics, α2-adrenergic agonists and sometimes benzodiazepines. In some cases, behavioural treatment may provide temporary control of symptoms. A small proportion of patients have disabling, medically refractory tics or experience unbearable side effects from the medication. It is these patients who have been potential candidates for neurosurgical interventions. Many different ablative surgeries have been carried out in TS throughout the history of surgical treatment of this disorder. Frontal lobe operations have included prefrontal lobotomies and bimedial frontal leucotomies. The limbic system has been targeted using limbic leucotomy and anterior cingulotomy. Thalamic operations have included lesioning of the medial, intralaminar, and ventrolateral thalamic nuclei. Infrathalamic lesions have been carried out at the level of Forel's fields (campotomies) and the zona incerta, and cerebellar surgery included dentatotomies. Since the first DBS procedures were carried out in 1999 for intractable TS, there have been several reports of dramatic clinical improvement in a small number of TS patients treated with thalamic and pallidal stimulation. This has brought marked enthusiasm and interest concerning the application of DBS in TS [83] [84] . Given the complexity of TS and concerns about the inappropriate selection of patients a working group has published recommendations for the selection and evaluation of patients 85, 86 which should be carefully considered if patients are being proposed for this still experimental procedure.
cOncluSIOn Surgical therapy, particularly DBS, for carefully screened and selected patients with medically intractable PD, ET, and possibly primary generalised dystonia is promising. An increasing number of published reports have demonstrated the relative safety of the procedure in addition to its remarkable benefit. Follow-up studies have demonstrated overall improvement in motor function, activities of daily living and quality of life, with postoperative reduction in medication requirement especially for PD. Reports of surgical therapy in other movement disorders such as chorea and tourette's syndrome although limited are promising as well. The hope is that with further improvement of the understanding of basal ganglia circuitry, neuroimaging, electrophysiological recording as well as stereotactic techniques, surgical therapy may improve other motor symptoms that are resistant to current medical and surgical therapies. 
